Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Total Non-Current Liabilities (2023 - 2026)

Prelude Therapeutics' Total Non-Current Liabilities history spans 4 years, with the latest figure at $56.7 million for Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities rose 61.69% to $56.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $56.7 million, a 61.69% increase, with the full-year FY2025 number at $69.8 million, up 70.48% from a year prior.
  • Total Non-Current Liabilities hit $56.7 million in Q1 2026 for Prelude Therapeutics, down from $69.8 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for PRLD hit a ceiling of $69.8 million in Q4 2025 and a floor of $33.1 million in Q1 2024.
  • Historically, Total Non-Current Liabilities has averaged $41.9 million across 4 years, with a median of $37.4 million in 2023.
  • The widest YoY moves for Total Non-Current Liabilities: up 70.48% in 2025, down 11.48% in 2025.
  • Tracing PRLD's Total Non-Current Liabilities over 4 years: stood at $37.2 million in 2023, then rose by 10.02% to $41.0 million in 2024, then skyrocketed by 70.48% to $69.8 million in 2025, then dropped by 18.84% to $56.7 million in 2026.
  • Business Quant data shows Total Non-Current Liabilities for PRLD at $56.7 million in Q1 2026, $69.8 million in Q4 2025, and $33.3 million in Q3 2025.